Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Abicipar Pegol in Neovascular Age-related Macular Degeneration
2014-004580-20Phase 3Completed
- Sponsor
- Allergan
- Start
- Jun 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abicipar pegol in exudative macular degeneration (2 arms), sponsored by Allergan. Primary endpoint: Stable vision at week 52. Started Jun 2015; status: completed.
02
Drugs
abicipar pegol
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2014-004580-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004580-20.